Compare Suncor Energy Inc. (SU) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Suncor Energy Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Suncor Energy Inc. trades at $75.94 (market cap $87.48B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Suncor Energy Inc. is far larger — about 17.9× Travere Therapeutics Inc. Common Stock's market cap, and Suncor Energy Inc. pays a 2.26% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Suncor Energy Inc. for 57 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SU | TVTX | |
|---|---|---|
Market Cap | $87.48B | $4.88B |
Volume | 3,692,639 | 1,668,577 |
Sector | Energy | Health |
52-Week High | $75.89 | $67.52 |
52-Week Low | $38.17 | $26.79 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $94.00B | $5.01B |
Dividend Yield | 2.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Suncor Energy (SU) trades at $75.89, up 3.24% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with a P/E of 14.32, net income margin of 14.7%, and consistent cash flow generation. Recent news highlights strategic asset divestitures and leadership transitions, while analyst consensus remains strongly positive with 74% buy ratings.
Outlook remains favorable given SU's integrated oil sands operations and aggressive shareholder returns through dividends and buybacks. Key risks include commodity price volatility and operational challenges, but the company's strong balance sheet and improving debt metrics provide stability. Current valuation appears reasonable relative to earnings potential.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
